NO994850L - Farmakologiske midler - Google Patents
Farmakologiske midlerInfo
- Publication number
- NO994850L NO994850L NO994850A NO994850A NO994850L NO 994850 L NO994850 L NO 994850L NO 994850 A NO994850 A NO 994850A NO 994850 A NO994850 A NO 994850A NO 994850 L NO994850 L NO 994850L
- Authority
- NO
- Norway
- Prior art keywords
- pharmacological agents
- glurs
- selective
- antagonists
- receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4279597P | 1997-04-07 | 1997-04-07 | |
| PCT/US1998/006905 WO1998045270A1 (en) | 1997-04-07 | 1998-04-06 | Pharmacological agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO994850D0 NO994850D0 (no) | 1999-10-05 |
| NO994850L true NO994850L (no) | 1999-10-05 |
Family
ID=21923795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO994850A NO994850L (no) | 1997-04-07 | 1999-10-05 | Farmakologiske midler |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6242462B1 (id) |
| EP (1) | EP0980358A4 (id) |
| JP (1) | JP2001521505A (id) |
| KR (1) | KR20010006075A (id) |
| CN (1) | CN1259126A (id) |
| AU (1) | AU734657B2 (id) |
| BR (1) | BR9809071A (id) |
| CA (1) | CA2285192A1 (id) |
| EA (1) | EA199900912A1 (id) |
| HU (1) | HUP0002030A3 (id) |
| ID (1) | ID23013A (id) |
| IL (1) | IL132086A0 (id) |
| NO (1) | NO994850L (id) |
| NZ (1) | NZ337827A (id) |
| PL (1) | PL336068A1 (id) |
| TR (1) | TR199902449T2 (id) |
| WO (1) | WO1998045270A1 (id) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1230174C (zh) | 1999-07-06 | 2005-12-07 | 伊莱利利公司 | 治疗偏头痛的选择性iGluR5受体拮抗剂 |
| ATE240299T1 (de) | 1999-07-06 | 2003-05-15 | Lilly Co Eli | Diester prodrugs von decahydroischinoline-3- carbonsäure |
| EP1257545A1 (en) | 1999-12-22 | 2002-11-20 | Eli Lilly And Company | SELECTIVE iGLUR 5? RECEPTOR ANTAGONISTS |
| US6855725B2 (en) | 2001-01-05 | 2005-02-15 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
| US7205313B2 (en) | 2001-01-05 | 2007-04-17 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
| MXPA03005982A (es) * | 2001-01-05 | 2003-09-10 | Lilly Co Eli | Antagonistas de receptores de aminoacidos excitadores. |
| AU2002241565A1 (en) * | 2001-01-05 | 2002-07-16 | Eli Lilly And Company | Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders |
| US6924294B2 (en) | 2001-01-05 | 2005-08-02 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
| US6953805B2 (en) | 2001-01-05 | 2005-10-11 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
| WO2002058691A1 (en) * | 2001-01-23 | 2002-08-01 | Neurosearch A/S | Use of non-competitive and selective glur5 antagonists as glutamate receptor modulating compounds |
| DK1511741T3 (da) | 2002-04-26 | 2013-01-21 | Lilly Co Eli | Esterderivater af en decahydroisoquinolin-3-carboxylsyre som analgetika |
| US20050101597A1 (en) * | 2003-07-10 | 2005-05-12 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitior and a non-NMDA glutamate modulator for the treatment of central nervous system damage |
| CA2580730C (en) * | 2003-09-25 | 2015-01-13 | Cenomed, Inc. | Tetrahydroindolone derivatives for treatment of neurological conditions |
| US20050107439A1 (en) * | 2003-11-10 | 2005-05-19 | Helton David R. | Composition and method for treating emesis |
| PL2083811T3 (pl) | 2006-11-22 | 2017-05-31 | Clinical Research Associates, Llc | Sposoby leczenia zespołu downa, zespołu łamliwego chromosomu x oraz autyzmu |
| CA2686816A1 (en) | 2007-01-16 | 2008-07-24 | The Johns Hopkins University | Use of various glutamate receptor antagonists for delaying or preventing platelet activity or for treating or preventing a thrombotic disease or disorder |
| WO2009062134A1 (en) * | 2007-11-09 | 2009-05-14 | Cenomed Biosciences, Llc | Treatment of post-traumatic stress disorder with tetrahydroindolone arylpiperazine compounds |
| US20090264443A1 (en) * | 2008-04-18 | 2009-10-22 | David Helton | Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds |
| US20130058915A1 (en) | 2010-03-02 | 2013-03-07 | Children's Medica Center Corporation | Methods and compositions for treatment of angelman syndrome and autism spectrum disorders |
| US20110294879A1 (en) | 2010-05-28 | 2011-12-01 | Xenoport, Inc. | Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders |
| WO2012009646A1 (en) | 2010-07-15 | 2012-01-19 | Xenoport, Inc. | Methods of treating fragile x syndrome, down's syndrome, autism and related disorders |
| KR101746944B1 (ko) * | 2015-09-23 | 2017-06-14 | 주식회사 포스코 | 도장 선영성이 우수한 도금강판의 제조방법 및 이에 의해 제조된 도금강판 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5284957A (en) | 1992-09-03 | 1994-02-08 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
| US5446051A (en) | 1994-05-31 | 1995-08-29 | Eli Lilly And Company | Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists |
| US5731348A (en) * | 1995-02-15 | 1998-03-24 | Bearsden Bio, Inc. | Alkylcarboxy amino acids-modulators of the kainate receptor |
-
1998
- 1998-04-06 WO PCT/US1998/006905 patent/WO1998045270A1/en not_active Ceased
- 1998-04-06 IL IL13208698A patent/IL132086A0/xx unknown
- 1998-04-06 AU AU69555/98A patent/AU734657B2/en not_active Ceased
- 1998-04-06 KR KR1019997009153A patent/KR20010006075A/ko not_active Withdrawn
- 1998-04-06 NZ NZ337827A patent/NZ337827A/xx unknown
- 1998-04-06 ID IDW991132A patent/ID23013A/id unknown
- 1998-04-06 HU HU0002030A patent/HUP0002030A3/hu unknown
- 1998-04-06 BR BR9809071-2A patent/BR9809071A/pt not_active IP Right Cessation
- 1998-04-06 CA CA002285192A patent/CA2285192A1/en not_active Abandoned
- 1998-04-06 EP EP98915346A patent/EP0980358A4/en not_active Withdrawn
- 1998-04-06 EA EA199900912A patent/EA199900912A1/ru unknown
- 1998-04-06 TR TR1999/02449T patent/TR199902449T2/xx unknown
- 1998-04-06 US US09/402,174 patent/US6242462B1/en not_active Expired - Fee Related
- 1998-04-06 CN CN98805687A patent/CN1259126A/zh active Pending
- 1998-04-06 JP JP54212798A patent/JP2001521505A/ja active Pending
- 1998-04-06 PL PL98336068A patent/PL336068A1/xx unknown
-
1999
- 1999-10-05 NO NO994850A patent/NO994850L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EA199900912A1 (ru) | 2000-04-24 |
| HUP0002030A2 (hu) | 2001-04-28 |
| TR199902449T2 (xx) | 2000-07-21 |
| PL336068A1 (en) | 2000-06-05 |
| EP0980358A4 (en) | 2001-02-07 |
| AU6955598A (en) | 1998-10-30 |
| US6242462B1 (en) | 2001-06-05 |
| CA2285192A1 (en) | 1998-10-15 |
| HUP0002030A3 (en) | 2002-01-28 |
| ID23013A (id) | 1999-12-30 |
| AU734657B2 (en) | 2001-06-21 |
| BR9809071A (pt) | 2000-08-01 |
| IL132086A0 (en) | 2001-03-19 |
| CN1259126A (zh) | 2000-07-05 |
| KR20010006075A (ko) | 2001-01-15 |
| JP2001521505A (ja) | 2001-11-06 |
| NZ337827A (en) | 2000-12-22 |
| WO1998045270A1 (en) | 1998-10-15 |
| NO994850D0 (no) | 1999-10-05 |
| EP0980358A1 (en) | 2000-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA199900912A1 (ru) | Фармацевтические средства | |
| DK1208095T3 (da) | Dibenzopyraner som glucocorticoidreceptorantagonister til behandling af diabetes | |
| EE200200355A (et) | EP4 retseptori selektiivsed agonistid osteoporoosi raviks | |
| DK0806952T3 (da) | Progesteronantagonister til fremstillingen af lægemidler til behandling af dysfunktionelle uterine blødninger | |
| BR0010215A (pt) | Derivados de indolina como antagonistas de progesterona | |
| EA199700156A1 (ru) | Производные индола как антагонисты рецептора 5-нт | |
| TR199801255T2 (xx) | Vitronektin resept�r antagonistleri. | |
| NO20032360D0 (no) | EP4 reseptor selektive agonister for behandling av osteoporose | |
| PT1349839E (pt) | Derivados de feniletenilo ou feniletinilo como antagonistas do receptor de glutamato | |
| DK0901470T3 (da) | Indolderivater egnede som endothelinreceptorantagonister | |
| NO20016246D0 (no) | Selektiv iGluR5 reseptorantagonist for behandling av migrene | |
| NO20034122D0 (no) | Sammensmeltede pyridinderivater for anvendelse som vanilloidreseptorantagonister for behandling av smerte | |
| IT1307900B1 (it) | Antagonisti iii del recettore ccr-3. | |
| NO20020574D0 (no) | Substituerte 1,5-dihydropyrrol-2-onderivater som er virksomme som NMDA-reseptorantagonister for behandlingen av smertetilstanden | |
| NO993350L (no) | Vitronectin-reseptor-antagonister | |
| IT1308657B1 (it) | Antagonisti ii del recettore ccr-3. | |
| ATE293448T1 (de) | Benzo(d)azepin-derivative als 5-ht6-rezeptor- antagonisten | |
| NO20002217L (no) | Cyclopentan-heptansyre, 2-heteroarylalkenylderivater som terapeutiske midler | |
| TR200002896T2 (tr) | Kalsilitik Bileşimler | |
| ATE245156T1 (de) | Aryl-annellierte disubstituierte pyridine : nk3 rezeptor-liganden | |
| TR199700956T1 (xx) | Indazolkarboksamidler. | |
| DK0983275T3 (da) | Nye triptolidderivater, der er nyttige til behandling af autoimmune sygdomme | |
| NO20014855L (no) | N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister | |
| DK0912556T3 (da) | Indolinderivater, der er anvendelige som 5-HT-2C-receptorantagonister | |
| EE9700309A (et) | AII-retseptori antagonistide uus farmakoloogiline kasutus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |